Spectranetics has received the CE Mark approval for its next-generation ThromCat XT thrombus removal system, a single-use, disposable device used to remove the thrombus from native coronary arteries and infra-inguinal arteries.The launch of the product will commence immediately within the European Union.
The Colorado Springs, Colo.-based company said the approval triggers a milestone payment of $1.5 million pursuant to its amended development and regulatory services agreement with Kensey Nash.
The updated ThromCat XT system generates a consistent vacuum pressure at the tip of the catheter to draw thrombus into the extraction ports where it is then macerated by an internal helix, according to Spectranetics. Without further contact with the blood stream, the thrombus is then transported to an external collection bag.
The company also noted that ThromCat XT is offered in 150cm length to treat vessels from 2.5 to 7 mm in diameter.